Potapenko I, et al. - Given that the number of patients receiving anti‐VEGF therapy has increased rapidly since its introduction in Denmark in 2007, putting considerable pressure on the public healthcare system, researchers sought to describe this growth and identify the factors driving it. Between 2007 and 2019, data on the treatment of the entire population of neovascular AMD patients in the Capital Region of Denmark was retrieved. The age and sex standardized incidences of first-time treatment and changes in the duration of treatment have been analysed. From 576 in 2007 to 3,684 in 2019, the number of patients undergoing active care has risen. The treatment incidences and modelling recorded in this study could help future ophthalmology services planning to be more informed and precise.